Methylene blue (methylthioninium chloride) is a synthetic thiazine dye, first made as a textile colourant in 1876, that later became a medicine. In the United States it is a prescription drug with one FDA-approved indication: acquired methemoglobinemia, a condition in which the iron in haemoglobin is oxidised from the ferrous to the ferric state and can no longer carry oxygen properly. In that setting it is given intravenously by a clinician, typically at 1 mg/kg, and it works as a redox agent that is converted to leucomethylene blue and restores haemoglobin's oxygen-binding capacity. Clinicians also use it off-label in hospital for vasoplegic shock and for ifosfamide-induced encephalopathy. None of these are wellness services.
What has brought methylene blue into recovery and longevity conversations is a separate idea: at very low doses it can shuttle electrons within the mitochondrial electron transport chain, in effect bypassing dysfunctional components of it. That mechanism has been used to market low-dose methylene blue as a nootropic and anti-ageing compound for memory, focus, mood, and energy, sold largely through telehealth subscriptions and compounding pharmacies rather than through studios. It became a visible social-media trend in 2025, with consumers posting blue tongues and longevity claims.
Praxium lists methylene blue for education and referral, not as a bookable studio modality. It is a prescription medication with a genuinely serious interaction profile, not a walk-in service, and the gap between the plausible mechanism and any proven wellness outcome is wide. If a facility discusses it at all, it belongs under clinician-directed medication management with a real medical intake, and the laboratory- or aquarium-grade dye sold as a stain is not a substitute for pharmaceutical-grade product and should never be ingested.
How methylene blue works
The mechanism is real and well characterised. Methylene blue is a redox-cycling compound: it accepts and donates electrons, is reduced to leucomethylene blue, and at low concentrations can act as an alternative electron carrier in the mitochondrial electron transport chain, shuttling electrons past dysfunctional complexes. It also inhibits nitric oxide synthase and guanylate cyclase, which is why it raises vascular tone in shock. In animal work going back to the 1970s, low-dose methylene blue increased brain cytochrome oxidase activity and improved memory retention. This is a plausible mitochondrial story, and it is the basis for every wellness claim made about the compound.
The human evidence for wellness outcomes is limited, small, and short-term. The most-cited study is a 2016 Radiology paper from UT Health San Antonio: a double-blind, randomised, placebo-controlled trial in 26 healthy adults aged 22 to 62, in which a single low oral dose increased fMRI response in the bilateral insular cortex, prefrontal cortex, parietal lobe, and occipital cortex, and produced about a 7 percent increase in correct responses during memory retrieval. A separate randomised controlled trial in 42 adults with claustrophobia found that 260 mg given after extinction training improved contextual memory at one month (p = 0.047), but the fear-extinction effect cut both ways: participants who still had moderate-to-high residual fear did worse on methylene blue than on placebo. These are single-dose experiments in small samples measuring laboratory tasks, not trials of daily supplementation for cognition, energy, or ageing, and no such trial exists.
Some findings run directly against the marketing. A 2023 study in the Journal of Cerebral Blood Flow and Metabolism gave 8 healthy volunteers placebo, 0.5 mg/kg, and 1 mg/kg methylene blue and measured an 8.4 percent and 8.3 percent reduction in global cerebral blood flow, with cerebral metabolic rate of oxygen falling 7.9 percent and 11.8 percent, a dose-dependent decrease. The authors read this as a hormetic effect, meaning clinically relevant doses may inhibit rather than augment brain metabolism and any benefit may require lower doses than those used clinically. The dementia evidence is also discouraging: LMTM, a stabilised derivative of methylene blue developed as a tau-aggregation inhibitor, failed its co-primary endpoints in a 15-month phase 3 trial of 891 people with mild-to-moderate Alzheimer's disease (Lancet, 2016), and a companion phase 3 in 220 people with behavioural-variant frontotemporal dementia also failed. A derivative failing at scale does not prove the parent compound useless, but it removes the strongest claim made for the category.
The safety profile is what most distinguishes methylene blue from a typical studio modality. It is a monoamine oxidase inhibitor, and combining it with serotonergic medication. SSRIs, SNRIs, MAOIs, certain opioids, dextromethorphan, can cause serotonin syndrome, which has been fatal. It is contraindicated in G6PD deficiency because of haemolysis risk. Doses at or above 7 mg/kg cause significant toxicity and single doses at or above 20 mg/kg cause severe intravascular haemolysis, so the therapeutic window matters. It also interferes with pulse oximetry readings, and it turns urine and the tongue blue-green, which is harmless but surprising. Consumer-grade product purity is a genuine and separate concern.
